{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T18:17:12Z","timestamp":1788891432510,"version":"build-2803163510"},"reference-count":30,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Cutaneous sarcoidosis presents with diverse morphologies, yet comparative data on systemic involvement, disease course and treatment response across subtypes remain limited. We conducted a 2-centre cross-sectional study including patients with histologically confirmed sarcoidosis identified through ICD codes, stratified into patients with and without cutaneous involvement and further by cutaneous subtype. Demographics, extracutaneous organ involvement, treatment response, clinical course and the organ leading to initial diagnosis were analysed. Among 125 patients (median age 53 years; 57% female), 99 had cutaneous sarcoidosis and 26 had no skin involvement. All major subtypes of cutaneous sarcoidosis were represented: plaque (39), papular (19), scar (15), subcutaneous (13) and lupus pernio (4); erythema nodosum (9) represented acute disease. Papular sarcoidosis (19) showed the mildest systemic involvement. Lymph nodes (64%) and lungs (48%) were most frequently affected with subtype specific variation. Skin lesions led to diagnosis in 78% of cases. Remission with topical therapy was rare (11%), whereas systemic glucocorticoids (21%) and other immunosuppressants (37%) showed higher response rates; sirolimus (11%), hydroxychloroquine (10%) and TNF inhibitors (8%) were most effective. Relapse occurred in 40% and 46% required long-term systemic therapy. Cutaneous sarcoidosis subtypes differ markedly in systemic involvement, treatment response and disease course, supporting biological heterogeneity and the need for individualized management.<\/jats:p>","DOI":"10.2340\/actadv.v106.adv-2026-0482","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T12:28:19Z","timestamp":1782131299000},"source":"Crossref","is-referenced-by-count":1,"title":["Organ Involvement and Treatment Response across Cutaneous Sarcoidosis Subtypes"],"prefix":"10.2340","volume":"106","author":[{"given":"Antonia","family":"Schett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Gabriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koray","family":"Tascilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8740-9615","authenticated-orcid":false,"given":"Georg","family":"Schett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0229-8931","authenticated-orcid":false,"given":"Carola","family":"Berking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Weninger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sticherling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1746-4250","authenticated-orcid":false,"given":"Georg","family":"Stary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"159550","doi-asserted-by":"crossref","unstructured":"Iannuzzi MC, Rybicki BA, Teirstein AS. . Sarcoidosis. N Engl J Med 2007; 357: 2153\u20132165.","DOI":"10.1056\/NEJMra071714"},{"key":"159551","doi-asserted-by":"crossref","unstructured":"Krausgruber T, Redl A, Barreca D, Doberer K, Romanovskaia D, Dobnikar L, et al. Single-cell and spatial transcriptomics reveal aberrant lymphoid developmental programs driving granuloma formation. Immunity 2023; 56: 289\u2013306.","DOI":"10.1016\/j.immuni.2023.01.014"},{"key":"159552","doi-asserted-by":"crossref","unstructured":"Crouser ED, Maier LA, Wilson KC, Bonham CA, Morgenthau AS, Patterson KC, et al. Diagnosis and detection of sarcoidosis. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med 2020; 201: e26\u2013e51.","DOI":"10.1164\/rccm.202002-0251ST"},{"key":"159553","doi-asserted-by":"crossref","unstructured":"S\u00e8ve P, Pacheco Y, Durupt F, Jamilloux Y, Gerfaud-Valentin M, Isaac S, et al. Sarcoidosis: a clinical overview from symptoms to diagnosis. Cells 2021; 10: 766.","DOI":"10.3390\/cells10040766"},{"key":"159554","doi-asserted-by":"crossref","unstructured":"Ma\u00f1\u00e1 J, Rubio-Rivas M, Villalba N, Marcoval J, Iriarte A, Molina-Molina M, et al. Multidisciplinary approach and long-term follow-up in a series of 640 consecutive patients with sarcoidosis: cohort study of a 40-year clinical experience at a tertiary referral center in Barcelona, Spain. Medicine 2017; 96: e7595.","DOI":"10.1097\/MD.0000000000007595"},{"key":"159555","doi-asserted-by":"crossref","unstructured":"Drent M, Lower EE, De Vries J. Sarcoidosis-associated fatigue. Eur Respir J 2012; 40: 255\u2013263.","DOI":"10.1183\/09031936.00002512"},{"key":"159556","doi-asserted-by":"crossref","unstructured":"Baughman RP, Valeyre D, Korsten P, Mathioudakis AG, Wuyts WA, Wells A, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J 2021; 58: 2004079.","DOI":"10.1183\/13993003.04079-2020"},{"key":"159557","unstructured":"Lower EE, Sturdivant M, Grate L, Baughman RP. Use of third-line therapies in advanced sarcoidosis. Clin Exp Rheumatol 2020; 38: 834\u2013840."},{"key":"159558","unstructured":"Wang A, Singh K, Ibrahim W, King B, Damsky W. The promise of JAK inhibitors for treatment of sarcoidosis and other inflammatory disorders with macrophage activation: a review of the literature. Yale J Biol Med 2020; 93: 187\u2013195."},{"key":"159559","doi-asserted-by":"crossref","unstructured":"Caplan A, Rosenbach M, Imadojemu S. Cutaneous sarcoidosis. Semin Respir Crit Care Med 2020; 41: 689\u2013699.","DOI":"10.1055\/s-0040-1713130"},{"key":"159560","doi-asserted-by":"crossref","unstructured":"Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H Jr, Bresnitz EA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164: 1885\u20131889.","DOI":"10.1164\/ajrccm.164.10.2104046"},{"key":"159561","doi-asserted-by":"crossref","unstructured":"Costabel U, Guzman J, Baughman RP. Systemic evaluation of a potential cutaneous sarcoidosis patient. Clin Dermatol 2007; 25: 303\u2013311.","DOI":"10.1016\/j.clindermatol.2007.03.008"},{"key":"159562","doi-asserted-by":"crossref","unstructured":"Hanno R, Needelman A, Eiferman RA, Callen JP. Cutaneous sarcoidal granulomas and the development of systemic sarcoidosis. Arch Dermatol 1981; 117: 203\u2013207.","DOI":"10.1001\/archderm.1981.01650040019012"},{"key":"159563","doi-asserted-by":"crossref","unstructured":"Boch K, Langan EA, Zillikens D, Ludwig RJ, Kridin K. Evaluation of clinical and laboratory characteristics of patients with cutaneous sarcoidosis: a single-center retrospective cohort study. Front Med 2022; 9: 980507.","DOI":"10.3389\/fmed.2022.980507"},{"key":"159564","doi-asserted-by":"crossref","unstructured":"Karada\u011f AS, Parish LC. Sarcoidosis: a great imitator. Clin Dermatol 2019; 37: 240\u2013254.","DOI":"10.1016\/j.clindermatol.2019.01.005"},{"key":"159565","doi-asserted-by":"crossref","unstructured":"Karakaya B, Kaiser Y, van Moorsel CHM, Grunewald J. L\u00f6fgren\u2019s syndrome: diagnosis, management, and disease pathogenesis. Semin Respir Crit Care Med 2017; 38: 463\u2013476.","DOI":"10.1055\/s-0037-1602380"},{"key":"159566","doi-asserted-by":"crossref","unstructured":"Baughman RP, Judson MA, Teirstein A, Lower EE, Lo K, Schlenker-Herceg R, et al. Chronic facial sarcoidosis including lupus pernio: clinical description and proposed scoring systems. Am J Clin Dermatol 2008; 9: 155\u2013161.","DOI":"10.2165\/00128071-200809030-00003"},{"key":"159567","doi-asserted-by":"crossref","unstructured":"Haimovic A, Sanchez M, Judson MA, Prystowsky S. Sarcoidosis: a comprehensive review and update for the dermatologist: part I. Cutaneous disease. J Am Acad Dermatol 2012; 66: 699.","DOI":"10.1016\/j.jaad.2011.11.965"},{"key":"159568","doi-asserted-by":"crossref","unstructured":"Yeung H, Farber S, Birnbaum BK, Dunham J, Ogdie A, Patterson KC, et al. Reliability and validity of cutaneous sarcoidosis outcome instruments among dermatologists, pulmonologists, and rheumatologists. JAMA Dermatol 2015; 151: 1317\u20131322","DOI":"10.1001\/jamadermatol.2015.2008"},{"key":"159569","doi-asserted-by":"crossref","unstructured":"Karada\u011f AS, Parish LC. Clinical phenotypes of cutaneous sarcoidosis: a review. Clin Dermatol 2019; 37: 660\u2013667.","DOI":"10.1016\/j.clindermatol.2019.01.005"},{"key":"159570","unstructured":"Yeung H, Farber S, Birnbaum BK, Dunham J, Ogdie A, Baughman RP, et al. The WASOG sarcoidosis organ assessment instrument: an update of a previous clinical tool. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31: 19\u201327."},{"key":"159571","doi-asserted-by":"crossref","unstructured":"Rosenbach M, Yeung H, Chu EY, Kim EJ, Payne AS, Takeshita J, et al. Reliability and convergent validity of the cutaneous sarcoidosis activity and morphology instrument for assessing cutaneous sarcoidosis. JAMA Dermatol 2013; 149: 550.","DOI":"10.1001\/jamadermatol.2013.60"},{"key":"159572","doi-asserted-by":"crossref","unstructured":"Stjepanovic M, Mihailovic-Vucinic V, Gvozdenovic BS, Milin-Lazovic J, Belic S, Djurdjevic N, et al. King\u2019s Sarcoidosis Questionnaire (KSQ) - validation study in Serbian speaking population of sarcoidosis patients. PLoS One 2023; 18: e0273126.","DOI":"10.1371\/journal.pone.0273126"},{"key":"159573","doi-asserted-by":"crossref","unstructured":"Belperio JA, Shaikh F, Abtin FG, Fishbein MC, Weigt SS, Saggar R, et al. Diagnosis and treatment of pulmonary sarcoidosis: a review. JAMA 2022; 327: 856\u2013867.","DOI":"10.1001\/jama.2022.1570"},{"key":"159574","doi-asserted-by":"crossref","unstructured":"Lo Schiavo A, Ruocco E, Gambardella A, O\u2019Leary RE, Gee S. Granulomatous dysimmune reactions (sarcoidosis, granuloma annulare, and others) on differently injured skin areas. Clin Dermatol 2014; 32: 646\u2013653.","DOI":"10.1016\/j.clindermatol.2014.04.012"},{"key":"159575","doi-asserted-by":"crossref","unstructured":"Drent M, Crouser ED, Grunewald J. Challenges of sarcoidosis and its management. N Engl J Med 2021; 385: 1018\u20131032.","DOI":"10.1056\/NEJMra2101555"},{"key":"159576","doi-asserted-by":"crossref","unstructured":"Zhang H, Costabel U, Dai H. The role of diverse immune cells in sarcoidosis. Front Immunol 2021; 12: 788502.","DOI":"10.3389\/fimmu.2021.788502"},{"key":"159577","doi-asserted-by":"crossref","unstructured":"Monast CS, Li K, Judson MA, Baughman RP, Wadman E, Watt R, et al. Sarcoidosis extent relates to molecular variability. Clin Exp Immunol 2017; 188: 444\u2013454.","DOI":"10.1111\/cei.12942"},{"key":"159578","doi-asserted-by":"crossref","unstructured":"Schupp JC, Freitag-Wolf S, Bargagli E, Mihailovi\u0107-Vu\u010dini\u0107 V, Rottoli P, Grubanovic A, et al. Phenotypes of organ involvement in sarcoidosis. Eur Respir J 2018; 51: 1700991.","DOI":"10.1183\/13993003.00991-2017"},{"key":"159579","doi-asserted-by":"crossref","unstructured":"Kahlmann V, Janssen Bon\u00e1s M, Moor CC, Grutters JC, Mostard RLM, van Rijswijk HNAJ, et al. First-line treatment of pulmonary sarcoidosis with prednisone or methotrexate. N Engl J Med 2025; 393: 231\u2013242.","DOI":"10.1056\/NEJMoa2501443"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46367\/54421","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46367\/54422","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46367\/54425","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46367\/54421","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T12:29:05Z","timestamp":1782131345000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/46367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":30,"URL":"https:\/\/doi.org\/10.2340\/actadv.v106.adv-2026-0482","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,22]]}}}